Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.
Identifieur interne : 003338 ( PubMed/Corpus ); précédent : 003337; suivant : 003339Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.
Auteurs : Patricia Pautier ; Eun Ji Nam ; Diane M. Provencher ; Anne L. Hamilton ; Giorgia Mangili ; Nadeem Ahmad Siddiqui ; Anneke M. Westermann ; Nicholas Simon Reed ; Philipp Harter ; Isabelle Ray-CoquardSource :
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [ 1525-1438 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- pathology : Sarcoma, Uterine Neoplasms.
- therapy : Sarcoma, Uterine Neoplasms.
- Combined Modality Therapy, Consensus, Female, Humans, Medical Oncology, Neoplasm Grading, Practice Guidelines as Topic, Societies, Medical.
Abstract
High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do not resemble proliferative-phase endometrial stroma. High-grade undifferentiated sarcomas are characterized by aggressive behavior and poor prognosis. Cyclin D1 has been reported as a diagnostic immunomarker for high-grade endometrial stromal sarcoma with an YWHAE-FAM22 rearrangement. YWHAE-FAM22 endometrial stromal sarcomas (ESS) represent a clinically aggressive subtype of ESS classified as high-grade endometrial sarcomas, and its distinction from the usual low-grade ESS with JAZF1 rearrangement and from HGUS with no identifiable molecular aberration may be important in guiding clinical management. Median age of the patients is between 55 and 60 years. The most common symptoms are vaginal bleeding, abdominal pain, and increasing abdominal girth.Disease is usually advanced with approximately 70% of the patients staged III to IV according to the International Federation of Gynecology and Obstetrics classification. Preferential metastatic locations include peritoneum, lungs, intra-abdominal lymph nodes, and bone. Median progression-free survival ranged from 7 to 10 months, and median overall survival ranged from 11 to 23 months. There is no clear prognostic factor identified for HGUS, not even stage. The standard management for HGUS consists of total hysterectomy and bilateral salpingo-oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy, have to be discussed in multidisciplinary staff meetings.
DOI: 10.1097/IGC.0000000000000281
PubMed: 25341584
Links to Exploration step
pubmed:25341584Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.</title><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation><nlm:affiliation>*Medical Department, Institut Gustave-Roussy, Villejuif, France (GINECO); †Division of Gynecologic Oncology, Yonsei University College of Medicine, Seoul, Korea (KGOG); ‡CHUM-Notre-Dame Hospital, Montreal, Québec, Canada (NCIC-CTG); §Peter Mac Callum, Cancer Centre, Royal Women's Hospital, University of Melbourne, Melbourne, Australia (ANZGOG); ∥Department of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, Milan, Italy (MITO); ¶NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom (SGCTG); #Academic Medical Center, Amsterdam, the Netherlands (DGOG); **Beatson Oncology Centre; and Gartnavel General Hospital, Glasgow, Scotland, United Kingdom (SGCTG); ††Kliniken Essen-Mitte, Essen, Germany (AGO); and ‡‡Medical Department, Centre Léon-Bérard, Lyon, France (GINECO).</nlm:affiliation></affiliation></author><author><name sortKey="Nam, Eun Ji" sort="Nam, Eun Ji" uniqKey="Nam E" first="Eun Ji" last="Nam">Eun Ji Nam</name></author><author><name sortKey="Provencher, Diane M" sort="Provencher, Diane M" uniqKey="Provencher D" first="Diane M" last="Provencher">Diane M. Provencher</name></author><author><name sortKey="Hamilton, Anne L" sort="Hamilton, Anne L" uniqKey="Hamilton A" first="Anne L" last="Hamilton">Anne L. Hamilton</name></author><author><name sortKey="Mangili, Giorgia" sort="Mangili, Giorgia" uniqKey="Mangili G" first="Giorgia" last="Mangili">Giorgia Mangili</name></author><author><name sortKey="Siddiqui, Nadeem Ahmad" sort="Siddiqui, Nadeem Ahmad" uniqKey="Siddiqui N" first="Nadeem Ahmad" last="Siddiqui">Nadeem Ahmad Siddiqui</name></author><author><name sortKey="Westermann, Anneke M" sort="Westermann, Anneke M" uniqKey="Westermann A" first="Anneke M" last="Westermann">Anneke M. Westermann</name></author><author><name sortKey="Reed, Nicholas Simon" sort="Reed, Nicholas Simon" uniqKey="Reed N" first="Nicholas Simon" last="Reed">Nicholas Simon Reed</name></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25341584</idno><idno type="pmid">25341584</idno><idno type="doi">10.1097/IGC.0000000000000281</idno><idno type="wicri:Area/PubMed/Corpus">003338</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.</title><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation><nlm:affiliation>*Medical Department, Institut Gustave-Roussy, Villejuif, France (GINECO); †Division of Gynecologic Oncology, Yonsei University College of Medicine, Seoul, Korea (KGOG); ‡CHUM-Notre-Dame Hospital, Montreal, Québec, Canada (NCIC-CTG); §Peter Mac Callum, Cancer Centre, Royal Women's Hospital, University of Melbourne, Melbourne, Australia (ANZGOG); ∥Department of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, Milan, Italy (MITO); ¶NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom (SGCTG); #Academic Medical Center, Amsterdam, the Netherlands (DGOG); **Beatson Oncology Centre; and Gartnavel General Hospital, Glasgow, Scotland, United Kingdom (SGCTG); ††Kliniken Essen-Mitte, Essen, Germany (AGO); and ‡‡Medical Department, Centre Léon-Bérard, Lyon, France (GINECO).</nlm:affiliation></affiliation></author><author><name sortKey="Nam, Eun Ji" sort="Nam, Eun Ji" uniqKey="Nam E" first="Eun Ji" last="Nam">Eun Ji Nam</name></author><author><name sortKey="Provencher, Diane M" sort="Provencher, Diane M" uniqKey="Provencher D" first="Diane M" last="Provencher">Diane M. Provencher</name></author><author><name sortKey="Hamilton, Anne L" sort="Hamilton, Anne L" uniqKey="Hamilton A" first="Anne L" last="Hamilton">Anne L. Hamilton</name></author><author><name sortKey="Mangili, Giorgia" sort="Mangili, Giorgia" uniqKey="Mangili G" first="Giorgia" last="Mangili">Giorgia Mangili</name></author><author><name sortKey="Siddiqui, Nadeem Ahmad" sort="Siddiqui, Nadeem Ahmad" uniqKey="Siddiqui N" first="Nadeem Ahmad" last="Siddiqui">Nadeem Ahmad Siddiqui</name></author><author><name sortKey="Westermann, Anneke M" sort="Westermann, Anneke M" uniqKey="Westermann A" first="Anneke M" last="Westermann">Anneke M. Westermann</name></author><author><name sortKey="Reed, Nicholas Simon" sort="Reed, Nicholas Simon" uniqKey="Reed N" first="Nicholas Simon" last="Reed">Nicholas Simon Reed</name></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name></author></analytic><series><title level="j">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</title><idno type="eISSN">1525-1438</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Combined Modality Therapy</term><term>Consensus</term><term>Female</term><term>Humans</term><term>Medical Oncology</term><term>Neoplasm Grading</term><term>Practice Guidelines as Topic</term><term>Sarcoma (pathology)</term><term>Sarcoma (therapy)</term><term>Societies, Medical</term><term>Uterine Neoplasms (pathology)</term><term>Uterine Neoplasms (therapy)</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Sarcoma</term><term>Uterine Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Sarcoma</term><term>Uterine Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Consensus</term><term>Female</term><term>Humans</term><term>Medical Oncology</term><term>Neoplasm Grading</term><term>Practice Guidelines as Topic</term><term>Societies, Medical</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do not resemble proliferative-phase endometrial stroma. High-grade undifferentiated sarcomas are characterized by aggressive behavior and poor prognosis. Cyclin D1 has been reported as a diagnostic immunomarker for high-grade endometrial stromal sarcoma with an YWHAE-FAM22 rearrangement. YWHAE-FAM22 endometrial stromal sarcomas (ESS) represent a clinically aggressive subtype of ESS classified as high-grade endometrial sarcomas, and its distinction from the usual low-grade ESS with JAZF1 rearrangement and from HGUS with no identifiable molecular aberration may be important in guiding clinical management. Median age of the patients is between 55 and 60 years. The most common symptoms are vaginal bleeding, abdominal pain, and increasing abdominal girth.Disease is usually advanced with approximately 70% of the patients staged III to IV according to the International Federation of Gynecology and Obstetrics classification. Preferential metastatic locations include peritoneum, lungs, intra-abdominal lymph nodes, and bone. Median progression-free survival ranged from 7 to 10 months, and median overall survival ranged from 11 to 23 months. There is no clear prognostic factor identified for HGUS, not even stage. The standard management for HGUS consists of total hysterectomy and bilateral salpingo-oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy, have to be discussed in multidisciplinary staff meetings.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25341584</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>24</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-1438</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9 Suppl 3</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</Title><ISOAbbreviation>Int. J. Gynecol. Cancer</ISOAbbreviation></Journal><ArticleTitle>Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.</ArticleTitle><Pagination><MedlinePgn>S73-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/IGC.0000000000000281</ELocationID><Abstract><AbstractText>High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do not resemble proliferative-phase endometrial stroma. High-grade undifferentiated sarcomas are characterized by aggressive behavior and poor prognosis. Cyclin D1 has been reported as a diagnostic immunomarker for high-grade endometrial stromal sarcoma with an YWHAE-FAM22 rearrangement. YWHAE-FAM22 endometrial stromal sarcomas (ESS) represent a clinically aggressive subtype of ESS classified as high-grade endometrial sarcomas, and its distinction from the usual low-grade ESS with JAZF1 rearrangement and from HGUS with no identifiable molecular aberration may be important in guiding clinical management. Median age of the patients is between 55 and 60 years. The most common symptoms are vaginal bleeding, abdominal pain, and increasing abdominal girth.Disease is usually advanced with approximately 70% of the patients staged III to IV according to the International Federation of Gynecology and Obstetrics classification. Preferential metastatic locations include peritoneum, lungs, intra-abdominal lymph nodes, and bone. Median progression-free survival ranged from 7 to 10 months, and median overall survival ranged from 11 to 23 months. There is no clear prognostic factor identified for HGUS, not even stage. The standard management for HGUS consists of total hysterectomy and bilateral salpingo-oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy, have to be discussed in multidisciplinary staff meetings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pautier</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>*Medical Department, Institut Gustave-Roussy, Villejuif, France (GINECO); †Division of Gynecologic Oncology, Yonsei University College of Medicine, Seoul, Korea (KGOG); ‡CHUM-Notre-Dame Hospital, Montreal, Québec, Canada (NCIC-CTG); §Peter Mac Callum, Cancer Centre, Royal Women's Hospital, University of Melbourne, Melbourne, Australia (ANZGOG); ∥Department of Gynecology and Obstetrics, IRCCS San Raffaele Hospital, Milan, Italy (MITO); ¶NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom (SGCTG); #Academic Medical Center, Amsterdam, the Netherlands (DGOG); **Beatson Oncology Centre; and Gartnavel General Hospital, Glasgow, Scotland, United Kingdom (SGCTG); ††Kliniken Essen-Mitte, Essen, Germany (AGO); and ‡‡Medical Department, Centre Léon-Bérard, Lyon, France (GINECO).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Eun Ji</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Provencher</LastName><ForeName>Diane M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Anne L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Mangili</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Nadeem Ahmad</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Anneke M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Nicholas Simon</ForeName><Initials>NS</Initials></Author><Author ValidYN="Y"><LastName>Harter</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ray-Coquard</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Gynecol Cancer</MedlineTA><NlmUniqueID>9111626</NlmUniqueID><ISSNLinking>1048-891X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="Y">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012509" MajorTopicYN="N">Sarcoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014594" MajorTopicYN="N">Uterine Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25341584</ArticleId><ArticleId IdType="doi">10.1097/IGC.0000000000000281</ArticleId><ArticleId IdType="pii">00009577-201411003-00015</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25341584
|texte= Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25341584" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |